Authors
Latest:
To Reduce Commercial Risk for Orphan Drugs, Transform ForecastingTo successfully commercialize orphan drugs, companies need to set aside general medicine strategies and adopt a more granular approach to identifying and capitalizing on commercial opportunities.
Latest:
Pharmaceutical Native AdvertisingA look into how native advertising works, what cost benefits they provide, and measuring their success.
Latest:
Commercialization Imperatives for Success in Rare DiseasesTo ensure patients have timely access to expensive new therapies, biopharma companies have to address commercialization challenges with innovative measures, even after getting regulatory approval.
Latest:
Money Isn't Everything: Beating Salary InflationAlan White explores alternative ways for life sciences firms to keep hold of experienced, qualified professionals as demand for pharmacovigilance skills soars.
Latest:
Value-Based Agency Contracting Clears a Path to Better Outcomes for AllThe healthcare industry’s ongoing shift from volume- to value-based contracting has set a compelling precedent for forward-thinking healthcare marketing agencies.
Latest:
Value-Based Agency Contracting Clears a Path to Better Outcomes for AllThe healthcare industry’s ongoing shift from volume- to value-based contracting has set a compelling precedent for forward-thinking healthcare marketing agencies.
Latest:
Pharma 4.0: Redefining Product Development and Regulatory OperationsSathyanarayanan Krishnamurthy looks at the potential impact of Pharma 4.0 on product development and regulatory operations.
Latest:
Three Technologies that Can Move Your BrandThe rise of digital has enhanced our ability to personalize our marketing messages and engage our target audiences more effectively
Latest:
Launch Strategies: Trends and Challenges for Biotech CompaniesMichael Kleinrock, of The IQVIA Institute for Human Data Science, will moderate a panel of launch and market access experts, as they discuss how biotech companies have addressed some key challenges to achieve launch success. Specific points will include an assessment of the overall outlook, what makes launches excellent, how to determine your optimal strategy, and questions that need to be addressed when deciding whether to launch or to partner. Live: Wednesday, Oct. 23, 2019 at 10am EDT On demand available after airing until Oct. 23, 2020 Register free
Latest:
For Payer Research, High Stakes are the Mother of All InventionAs payers increasingly stifle new drug launches, investors in biopharmaceutical companies pursue better sources of insights.
Latest:
Technology and Patients Intersect at Digital Pharma EastA look at highlights from the Digital Pharma East conference looking at technology and marketing innovation in pharma.
Latest:
Silent (R)evolution in Medical Affairs Through the Power of Partnerships and CollaborationsA look at how Medical Affairs is transitioning to a new and fundamental strategic role within pharma and ways MA can step up to own this role within a pharma company, particularly within emerging markets.
Latest:
Silent (R)evolution in Medical Affairs Through the Power of Partnerships and CollaborationsA look at how Medical Affairs is transitioning to a new and fundamental strategic role within pharma and ways MA can step up to own this role within a pharma company, particularly within emerging markets.
Latest:
Silent (R)evolution in Medical Affairs Through the Power of Partnerships and CollaborationsA look at how Medical Affairs is transitioning to a new and fundamental strategic role within pharma and ways MA can step up to own this role within a pharma company, particularly within emerging markets.
Latest:
Silent (R)evolution in Medical Affairs Through the Power of Partnerships and CollaborationsA look at how Medical Affairs is transitioning to a new and fundamental strategic role within pharma and ways MA can step up to own this role within a pharma company, particularly within emerging markets.
Latest:
Silent (R)evolution in Medical Affairs Through the Power of Partnerships and CollaborationsA look at how Medical Affairs is transitioning to a new and fundamental strategic role within pharma and ways MA can step up to own this role within a pharma company, particularly within emerging markets.
Latest:
Silent (R)evolution in Medical Affairs Through the Power of Partnerships and CollaborationsA look at how Medical Affairs is transitioning to a new and fundamental strategic role within pharma and ways MA can step up to own this role within a pharma company, particularly within emerging markets.
Latest:
Who is Driving the HTA Bus? And Where is it Headed?An Exploration of the Future of Pharmaceutical Value Assessments in the U.S.
Latest:
Who is Driving the HTA Bus? And Where is it Headed?An Exploration of the Future of Pharmaceutical Value Assessments in the U.S.
Latest:
Who is Driving the HTA Bus? And Where is it Headed?An Exploration of the Future of Pharmaceutical Value Assessments in the U.S.
Latest:
Who is Driving the HTA Bus? And Where is it Headed?An Exploration of the Future of Pharmaceutical Value Assessments in the U.S.
Latest:
Who is Driving the HTA Bus? And Where is it Headed?An Exploration of the Future of Pharmaceutical Value Assessments in the U.S.
Latest:
Lay the Tech Foundation for IPO SuccessMike Kean and Billy Tamulynas discuss the key components of growth-ready technology for early-stage pharma companies and how to make optimal use of them.
Latest:
Driving Success in Gene TherapyGetting real about the R&D capabilities required to win in the gene therapy space.
Latest:
Driving Success in Gene TherapyGetting real about the R&D capabilities required to win in the gene therapy space.
Latest:
Value-Based Planning Uncovers True Drivers of Cost Across Life Sciences OrganizationsExplicitly tying strategic planning to resource allocation boosts bottom-line productivity for pharma.
Latest:
Driving Success in Gene TherapyGetting real about the R&D capabilities required to win in the gene therapy space.
Latest:
Driving Success in Gene TherapyGetting real about the R&D capabilities required to win in the gene therapy space.
Latest:
AI in the R&D Value ChainIn comparison with other industries, the use of AI is modest in life sciences. However, even within life sciences, adoption of AI in regulated environments, such as in the R&D value chain, is further behind. Sivakumar Thiagarajan
Latest:
Emerging Pharma Must Pick Up Pace in Analytics Arms RaceMost emerging pharma companies still struggle to amass the computing power and assemble the teams to make use of the vast amounts of data now available to them, write Beth Beghou and Patrick Lezark.
